Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 8/20 | 0.58 |
| ▸ | NPY1R | P25929 | 3/20 | 0.54 |
| ▸ | NPY2R | P49146 | 3/20 | 0.54 |
| ▸ | NPY4R | P50391 | 3/20 | 0.54 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31105342 | 0.91 | GHSR (0.52) | GHSRNPY1RNPY2RNPY4R | |
| SCHEMBL22546756 | 0.91 | GHSR (0.58) | GHSR | |
| SCHEMBL29666286 | 0.90 | GHSR (0.59) | GHSR | |
| SCHEMBL31105609 | 0.90 | GHSR (0.53) | GHSRNPY1RNPY2RNPY4RUTS2R | |
| SCHEMBL30540726 | 0.89 | GHSR (0.62) | GHSR | |
| SCHEMBL31202576 | 0.89 | GHSR (0.66) | GHSRNPY1RNPY2RNPY4RUTS2R | |
| SCHEMBL31615095 | 0.88 | GHSR (0.58) | GHSR | |
| SCHEMBL30751948 | 0.88 | GHSR (0.56) | GHSR | |
| SCHEMBL31105637 | 0.88 | GHSR (0.60) | GHSR | |
| SCHEMBL29666294 | 0.88 | GHSR (0.56) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220016218-A1 | LIPOPHILIC PEPTIDE PRODRUGS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-01-20 | — | — | US | disclosed |
| US-20200323962-A1 | LIPOPHILIC PEPTIDE PRODRUGS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2020-10-15 | — | — | US | disclosed |
| WO-2019058367-A1 | LIPOPHILIC PEPTIDE PRODRUGS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220016218-A1 | LIPOPHILIC PEPTIDE PRODRUGS | VIP, SI, TMPRSS15 | GHSR 1990/4885NPY1R 1484/4885NPY2R 1637/4885 |
| US-20200323962-A1 | LIPOPHILIC PEPTIDE PRODRUGS | VIP, SI, TMPRSS15 | GHSR 1990/4885NPY1R 1484/4885NPY2R 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.